Download fulltext HTML
Tahmasebi Fard, Z., Rouhollah, F., & Nafisi, N. (2019). Serum Liver Proteins and 17. Research in Molecular Medicine (RMM), 6(4), 48–58. https://doi.org/10.18502/rmm.v6i4.4803

https://doi.org/10.18502/rmm.v6i4.4803

statistics

  • 245 Abstract Views
  • 150 PDF Views
  • 0 HTML Views

authors

  • Zahra Tahmasebi Fard

    Zahra Tahmasebi Fard

    Department of Cell and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
  • Fatemeh Rouhollah

    Fatemeh Rouhollah

    Department of Cell and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
  • Nahid Nafisi

    Nahid Nafisi

    Assistant Professor, Surgery Department, Iran University of Medical Science, Tehran, Iran

Published Date

  • Jul 14, 2019

Serum Liver Proteins and 17

Research in Molecular Medicine (RMM) / Research in Molecular Medicine (RMM): Volume 6, Issue No. 4 / Pages 48–58

Abstract

Background: Breast cancer is a hormone-dependent malignancy that is associated with estrogen and progesterone interactions. The liver is the most important organ to be affected by the metastasis of breast cancer, which causes functional impairment.


Aim: We compared levels of obesity, 17β-estradiol, and secreted proteins in postmenopausal women with breast cancer but without hepatic symptoms to those in healthy postmenopausal women.


Materials and Methods: We recruited 105 postmenopausal women with breast cancer but without any clinical hepatic symptoms based on a physician’s diagnosis, and 105 healthy postmenopausal women. After taking blood samples, we separated the serum and determined the levels of alanine aminotransferase (ALT), enzyme aspartate aminotransferase (AST), sex hormone-binding globulin (SHBG), and 17β-estradiol using an enzyme-linked immunosorbent assay (ELISA). The results were statistically analyzed using SPSS.


Results: The mean ages of the subjects in the cancer and control groups were 60.88 ± 0.85 and 55.56 ± 0.81 years, respectively. The exception ages (p=0.002), body mass index (BMI) values (p=0.033), serum glutamic oxaloacetic transaminase (SGOT) levels/AST levels (p=3.1*10−4), serum glutamic pyruvic transaminase (SGPT) levels/ALT levels(p=0.001), SHBG levels(p=0.014), and 17β-estradiol levels(p=0.003) in the serum differed significantly between the groups. Moreover, the mean serum 17β-estradiol (E2) levels and weights were higher in the cancer group than in the control group. Nevertheless, the mean serum levels of synthetic liver enzymes (SHBG, ALT, and AST) were lower in the cancer group than in the control group.


Conclusion: In general, the postmenopausal cancer patients had higher serum estrogen levels and BMIs than their healthy counterparts. Furthermore, the levels of liver enzymes apparently decreased in the cancer group, probably owing to liver malfunction.

References
[1] Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, et al. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer. 2005;6(5):391-401.

[2] Kaminska M, Ciszewski T, Lopacka-Szatan K, Miotla P, Staroslawska E. Breast cancer risk factors. Przeglad Menopauzalny. 2015;14(3):196-202. doi:10.5114/pm.2015.54346.

[3] Lawson JS, Tran D, Rawlinson WD. From Bittner to Barr: a viral, diet and hormone breast cancer aetiology hypothesis. Breast Cancer Res. 2001;3(2):81-5.

[4] Weinrich M, Weiß C, Schuld J, Rau BM. Liver Resections of Isolated Liver Metastasis in Breast Cancer: Results and Possible Prognostic Factors. HPB Surg. 2014;2014:6 pages. Article ID 893829. http://dx.doi.org/10.1155/2014/893829.

[5] Wyld L, Gutteridge E, Pinder SE, James JJ, Chan SY, Cheung KL, et al. Prognostic factors for patients with hepatic metastases from breast cancer. BJC. 2003;89(2):284- 90. doi:10.1038/sj.bjc.6601038.

[6] Russo J, Russo IH. The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol. 2006;102(1-5):89-96. doi:10.1016/j.jsbmb.2006.09.004.

[7] Burger HG. Androgen production in women. Fertil Steril. 2002;77(4):S3-5. doi:10.1016/S0015-0282(02)02985-0.

[8] Cavalieri E, Rogan E. Catechol quinones of estrogens in the initiation of breast, prostate, and other human cancers: keynote lecture. Ann N Y Acad Sci. 2006;1089:286-301.

[9] Almeida M, Laurent MR, Dubois V, Claessens F, O’Brien CA, Bouillon R, et al. Estrogens and androgens in skeletal physiology and pathophysiology. Physiol Rev. 2017;97(1):135-87.

[10] Haghighi N, Tahmasebifard Z, Nafisi N. Investigation of association between E326K in SHBG gene and breast cancer in Iranian females. Journal of Fasa University of Medical Sciences. 2015;5(2):289-95.

[11] Shimada N, Iwasaki M, Kasuga Y, Yokoyama S, Onuma H, Nishimura H, et al. Genetic polymorphisms in estrogen metabolism and breast cancer risk in casecontrol studies in Japanese, Japanese Brazilians and non-Japanese Brazilians. J Hum Genet. 2009;54(4):209-15.

[12] Ralph DA, Zhao LP, Aston CE, Manjeshwar S, Pugh TW, DeFreese DC, et al. Agespecific association of steroid hormone pathway gene polymorphisms with breast
cancer risk. Cancer. 2007;109(10):1940-8.

[13] Dorgan JF, Longcope C, Stephenson HE Jr, Falk RT, Miller R, Franz C, et al. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1996;5(7):533-9.

[14] Lamar CA, Dorgan JF, Longcope C, Stanczyk FZ, Falk RT, Stephenson HE Jr. Serum sex hormones and breast cancer risk factors in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2003;12(4):380-3. PMID:12692114.

[15] Lawenda, BD, Mondry TE, Johnstone PA. Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin. 2009;59(1):8-24.

[16] Hryb DJ, Nakhla AM, Kahn SM, St George J, Levy NC, Romas, et al. Sex hormonebinding globulin in the human prostate is locally synthesized and may act as an autocrine/paracrine effector. J Biol Chem. 2002;277(29):26618-22.

[17] Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. JNCI. 2003; 95(16):1218-26. PMID:12928347.

[18] Endogenous Hormones and Breast Cancer Collaborative Group, Key TJ, Appleby PN, Reeves GK, Roddam AW, Helzlsouer KJ, et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. BJC.2011;105(5):709-22. doi:10.1038/bjc.2011.254.

[19] Fourkala EO, Zaikin A, Burnell M, Gentry-Maharaj A, Ford J, Gunu R, et al. Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. Endocr Relat Cancer. 2012;19(2):137-147. doi: 10.1530/ERC-11-0310.

[20] Lim VW, Li J, Gong Y, Jin A, Yuan JM, Yong EL, et al. Serum estrogen receptor bioactivity and breast cancer risk among postmenopausal women. Endocr Relat Cancer. 2014;21(2):263-73.

[21] Adly L, Hill D, Sherman ME, Sturgeon SR, Fears T, Mies C, et al. Serum concentrations of estrogens, sex hormone-binding globulin, and androgens and risk of breast cancer in postmenopausal women. Int J Cancer. 2006;119(10):2402-7.

[22] Fortunati N, Catalano MG, Boccuzzi G, Frairia R. Hormone-binding globulin (SHBG), estradiol and breast cancer. Mol Cell Endocrinol. 2010;316(1):86-92.

[23] Damodar G, Smitha T, Gopinath S, Vijayakumar S, Rao YA. An evaluation of hepatotoxicity in breast cancer patients receiving injection doxorubicin. Annals of Medical and Health Science Research. 2014;4(1):74-9. doi: 10.4103/2141-9248.126619.